Holen Sie sich die Stockscreener-App
1.37
3.52%
-0.05
Handel nachbörslich:
1.37
Schlusskurs vom Vortag:
$1.42
Offen:
$1.41
24-Stunden-Volumen:
1.92M
Relative Volume:
0.46
Marktkapitalisierung:
$1.13B
Einnahmen:
$711.41M
Nettoeinkommen (Verlust:
$-133.73M
KGV:
-7.2105
EPS:
-0.19
Netto-Cashflow:
$-199.99M
1W Leistung:
-3.52%
1M Leistung:
-23.89%
6M Leistung:
-5.52%
1J Leistung:
+11.38%
1-Tages-Spanne:
$1.37
$1.42
1-Wochen-Bereich:
$1.37
$1.46
52-Wochen-Spanne:
$1.15
$2.035
Opko Health Inc Stock (OPK) Company Profile
Firmenname
Opko Health Inc
Sektor
Branche
Telefon
305-575-4181
Adresse
4400 BISCAYNE BLVD., MIAMI, FL
Vergleichen Sie OPK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.37 | 1.13B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
421.85 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
184.96 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
406.65 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
100.26 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
141.22 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-29 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-24 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-11-25 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-03-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-06-21 | Bestätigt | Standpoint Research | Buy |
| 2016-06-03 | Eingeleitet | Standpoint Research | Buy |
| 2016-03-31 | Bestätigt | Barrington Research | Outperform |
| 2015-10-16 | Eingeleitet | JP Morgan | Overweight |
| 2015-09-11 | Herabstufung | Jefferies | Buy → Hold |
| 2015-03-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2014-05-12 | Bestätigt | Oppenheimer | Outperform |
| 2014-03-14 | Eingeleitet | Oppenheimer | Outperform |
| 2013-11-13 | Bestätigt | Ladenburg Thalmann | Buy |
| 2013-05-30 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-10-22 | Eingeleitet | Barrington Research | Outperform |
| 2011-12-01 | Bestätigt | Ladenburg Thalmann | Buy |
| 2011-07-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Opko Health Inc Aktie (OPK) Neueste Nachrichten
OPKO Health Target of Unusually Large Options Trading (NASDAQ:OPK) - MarketBeat
Altshuler Shaham Ltd Makes New $2.08 Million Investment in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Norges Bank Acquires Shares of 1,127,468 OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Bone Cancer Drugs Market Deep Research 2025-2032 | Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc. - openPR.com
OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025 - GlobeNewswire
OPKO Health, Inc. (NASDAQ:OPK) boasts of bullish insider sentiment with 52% ownership and they have been buying lately - Yahoo Finance
Q3 Earnings Forecast for OPKO Health Issued By HC Wainwright - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 125,000 Shares - MarketBeat
OPKO Health (NASDAQ:OPK) Earns "Buy" Rating from HC Wainwright - MarketBeat
Quote - OPKO Health, Inc.
NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program - MarketScreener
Opko Health’s CEO Phillip Frost buys $169,712 in stock - Investing.com Australia
Hypopituitarism Market on Track for Major Expansion by 2032, - openPR.com
Hypopituitarism Market on Track for Major Expansion by 2032, According to DelveInsight | OPKO Health, Lumos Pharma, Versartis Inc., I-Mab Biopharma Co. Ltd - The Globe and Mail
Opko Health's CEO Phillip Frost buys $169,712 in stock By Investing.com - Investing.com Canada
Opko Health’s CEO Phillip Frost buys $169,712 in stock By Investing.com - Investing.com South Africa
Opko Health's CEO Phillip Frost buys $169,712 in stock - Investing.com
Weekly Top Insider Buys Highlight for the Week of April 12 - GuruFocus
Opko health CEO Phillip Frost buys $184,650 in stock By Investing.com - Investing.com India
Opko health CEO Phillip Frost buys $184,650 in stock - Investing.com
H.C. Wainwright maintains $3 target, Buy on Opko Health stock By Investing.com - Investing.com UK
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
OPKO Health authorizes $100 million increase to share buyback program - MSN
OPKO Health Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
OPKO Health (NASDAQ:OPK) Sees Unusually-High Trading Volume After Insider Buying Activity - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Sees Large Increase in Short Interest - MarketBeat
Phillip Md Et Al Frost Buys 100,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock - MarketBeat
Iron Mountain, EOG, Oklo, NuScale, Opko: Insider Moves Unveiled - TipRanks
OPKO Health Boosts Stock Buyback Program by $100 Million - marketscreener.com
Opko Health Announces $100 Million Increase To Its Existing Share Repurchase Program - MarketScreener
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program - GlobeNewswire
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
Esoteric Testing Market Deep Research 2025-2032 | LabCorp, Quest Diagnostics, OPKO Health, Miraca Holdings - openPR.com
Global Clinical Laboratory Tests Market Set to Witness - openPR.com
Opko health CEO Phillip Frost buys $164,850 in stock By Investing.com - Investing.com Canada
Finanzdaten der Opko Health Inc-Aktie (OPK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):